Skip to Content

Wen-Jen Hwu, M.D., Ph.D.

Present Title & Affiliation

Primary Appointment

Professor, Department of Melanoma Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Office Address

The University of Texas MD Anderson Cancer Center
1515 Holcombe Boulevard
Unit Number: 430
Houston, TX 77030
Room Number: FC11.3010
Phone: 713-792-2921
Fax: 713-745-1046

Education & Training

Degree-Granting Education

1982 University of California College of Medicine, Irvine, CA, M.D., Medicine
1976 Carnegie-Mellon University, Pittsburgh, PA, Ph.D., Chemistry
1973 Duquesne University, Pittsburgh, PA, M.S., Chemistry
1971 National Tsinghua University, Hsinchu, Taiwan, B.S., Chemistry

Postgraduate Training

7/1986-6/1989 Postdoctoral Fellowship in Medical Oncology, Section of Medical Oncology, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT
6/1982-6/1985 Internship and Residency in Internal Medicine, University of California College of Medicine, UCI Medical Center, Orange, CA

Board Certifications

1989 American Board of Medical Oncology
1985 American Board of Internal Medicine


Academic Appointments

Consulting Attending, Lyndon B. Johnson General Hospital, Houston, TX, 4/2006-6/2010

Administrative Appointments/Responsibilities

Special Assistant & Consultant, Physicians Network, The University of Texas MD Anderson Cancer Center, Houston, TX, 9/2010-7/2012

Other Appointments/Responsibilities

Chairman, Women in Cancer Research (WICR), American Association of Cancer Research (AACR), Philadelphia, PA, 4/2012-present
Council Member, Women in Cancer Research (WICR), American Association of Cancer Research (AACR), Philadelphia, PA, 2009-present
Member, Southwest Oncology Group (SWOG), Ann Arbor, MI, 2008-present
Member, American Association for Cancer Research (AACR) Grants Review Committee, Philadelphia, PA, 2008-2010
Member, NCI Cancer Center Clinical Protocol Scientific Review and Monitoring Committee, Bethesda, MD, 1/2005-present

Honors and Awards

2013-present Outstanding Post Graduate Physician Assistant Fellowship Preceptor, The University of Texas MD Anderson Cancer Center - PA Education
2007 Teaching Award, Hematology-Oncology Fellowship Program, Lyndon B. Johnson General Hospital, Division of Cancer Medicine, UT M.D. Anderson Cancer Center
2004 Stripes Award for the Best Melanoma Doctor, Billy Foundation
1995 Special Contribution Award, VA Connecticut Health Care Systems

Selected Publications

Peer-Reviewed Original Research Articles

1. Yorio JT, Mays SR, Ciurea AM, Cohen PR, Wang WL, Hwu WJ, Gonzalez N, Richard JL, Kim KB. Case of vemurafenib-induced Sweet's syndrome. J Dermatol. e-Pub 3/12/2014. PMID: 24617955.
2. Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, Wolchok JD, Hersey P, Joseph RW, Weber JS, Dronca R, Gangadhar TC, Patnaik A, Zarour H, Joshua AM, Gergich K, Elassaiss-Schaap J, Algazi A, Mateus C, Boasberg P, Tumeh PC, Chmielowski B, Ebbinghaus SW, Li XN, Kang SP, Ribas A. Safety and Tumor Responses with Lambrolizumab (Anti-PD-1) in Melanoma. N Engl J Med 369(2):134-44, 7/11/2013. e-Pub 6/2/2013. PMID: 23724846.
3. Vence LM, Wang C, Pappu H, Anson RE, Patel TA, Miller P, Bassett R, Lizee G, Overwijk WW, Komanduri K, Benjamin C, Alvarado G, Patel SP, Kim K, Papadopoulos NE, Bedikian AY, Homsi J, Hwu WJ, Boyd R, Radvanyi L, Hwu P. Chemical Castration of Melanoma Patients Does Not Increase the Frequency of Tumor-specific CD4 and CD8 T Cells After Peptide Vaccination. J Immunother 36(4):276-86, 5/2013. PMID: 23603862.
4. Curry JL, Falchook GS, Hwu WJ, Torres-Cabala CA, Duvic M, Tetzlaff MT, Prieto VG. Changes in Tumor Morphology and Cyclin-Dependent Kinase Inhibitor Expression in Metastatic Melanoma Treated With Selective Second-Generation BRAF Inhibitor. Am J Dermatopathol 35(1):125-8, 2/2013. e-Pub 8/8/2012. PMID: 22878367.
5. Radvanyi LG, Bernatchez C, Zhang M, Fox PS, Miller P, Chacon J, Wu R, Lizee G, Mahoney S, Alvarado G, Glass M, Johnson VE, McMannis JD, Shpall E, Prieto V, Papadopoulos N, Kim K, Homsi J, Bedikian A, Hwu WJ, Patel S, Ross MI, Lee JE, Gershenwald JE, Lucci A, Royal R, Cormier JN, Davies MA, Mansaray R, Fulbright OJ, Toth C, Ramachandran R, Wardell S, Gonzalez A, Hwu P. Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients. Clin Cancer Res 18(24):6758-70, 12/2012. e-Pub 10/2012. PMCID: PMC3525747.
6. Noor R, Bedikian AY, Mahoney S, Bassett R, Kim K, Papadopoulos N, Hwu WJ, Hwu P, Homsi J. Comparison of two dosing schedules of palonosetron for the prevention of nausea and vomiting due to interleukin-2-based biochemotherapy. Support Care Cancer 20(10):2583-8, 10/2012. e-Pub 1/25/2012. PMID: 22274951.
7. Kim J, Lazar AJ, Davies MA, Homsi J, Papadopoulos NE, Hwu WJ, Bedikian AY, Woodman SE, Patel SP, Hwu P, Kim KB. BRAF, NRAS and KIT sequencing analysis of spindle cell melanoma. J Cutan Pathol 39(9):821-5, 9/2012. e-Pub 7/2012. PMID: 22809251.
8. Chen LL, Gouw L, Sabripour M, Hwu WJ, Benjamin RS. Combining targeted therapy with immunotherapy (interferon-α): Rational, efficacy in gastrointestinal stromal tumor model and implications in other malignancies. Oncoimmunology 1(5):773-776, 8/1/2012. PMCID: PMC3429591.
9. Daud A, Soon C, Dummer R, Eggermont AM, Hwu WJ, Grob JJ, Garbe C, Hauschild A. Management of pegylated interferon alpha toxicity in adjuvant therapy of melanoma. Expert Opin Biol Ther 12(8):1087-99, 8/2012. e-Pub 6/14/2012. PMID: 22694288.
10. Alvarado G, Noor R, Bassett R, Papadopoulos NE, Kim KB, Hwu WJ, Bedikian A, Patel S, Hwu P, Davies MA. Risk of intracranial hemorrhage with anticoagulation therapy in melanoma patients with brain metastases. Melanoma Res 22(4):310-5, 8/2012. e-Pub 5/2012. PMID: 22584956.
11. Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, Pitot HC, Hamid O, Bhatia S, Martins R, Eaton K, Chen S, Salay TM, Alaparthy S, Grosso JF, Korman AJ, Parker SM, Agrawal S, Goldberg SM, Pardoll DM, Gupta A, Wigginton JM. Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer. N Engl J Med 366(26):2455-65, 6/28/2012. e-Pub 6/2/2012. PMCID: PMC3563263.
12. Trinh VA, Hwu WJ. Ipilimumab in the treatment of melanoma. Expert Opin Biol Ther 12(6):773-82, 6/2012. e-Pub 4/14/2012. PMID: 22500861.
13. Bronstein Y, Ng CS, Rohren E, Ross MI, Lee JE, Cormier J, Johnson VE, Hwu WJ. PET/CT in the Management of Patients With Stage IIIC and IV Metastatic Melanoma Considered Candidates for Surgery: Evaluation of the Additive Value After Conventional Imaging. AJR Am J Roentgenol 198(4):902-8, 4/2012. PMID: 22451559.
14. Davies MA, Fox PS, Papadopoulos NE, Bedikian AY, Hwu WJ, Lazar AJ, Prieto VG, Culotta KS, Madden TL, Xu Q, Huang S, Deng W, Ng CS, Gupta S, Liu W, Dancey JE, Wright JJ, Bassett RL, Hwu P, Kim KB. Phase I study of the combination of sorafenib and temsirolimus in patients with metastatic melanoma. Clin Cancer Res 18(4):1120-8, 2/15/2012. e-Pub 1/5/2012. PMID: 22223528.
15. Pan T, Zhu J, Hwu WJ, Jankovic J. The Role of Alpha-Synuclein in Melanin Synthesis in Melanoma and Dopaminergic Neuronal Cells. PLoS One 7(9):e45183, 2012. e-Pub 9/19/2012. PMID: 23028833.
16. Bedikian AY, Wei C, Detry M, Kim KB, Papadopoulos NE, Hwu WJ, Homsi J, Davies M, McIntyre S, Hwu P. Predictive Factors for the Development of Brain Metastasis in Advanced Unresectable Metastatic Melanoma. Am J Clin Oncol 34(6):603-10, 12/2011. e-Pub 12/2010. PMID: 21150567.
17. Bronstein Y, Ng CS, Hwu P, Hwu WJ. Radiologic Manifestations of Immune-Related Adverse Events in Patients With Metastatic Melanoma Undergoing Anti-CTLA-4 Antibody Therapy. AJR Am J Roentgenol 197(6):W992-W1000, 12/2011. PMID: 22109345.
18. Patel SP, Kim KB, Papadopoulos NE, Hwu WJ, Hwu P, Prieto VG, Bar-Eli M, Zigler M, Dobroff A, Bronstein Y, Bassett RL, Vardeleon AG, Bedikian AY. A phase II study of gefitinib in patients with metastatic melanoma. Melanoma Res 21(4):357-63, 8/2011. PMCID: PMC3132394.
19. Bedikian AY, Silverman JA, Papadopoulos NE, Kim KB, Hagey AE, Vardeleon A, Hwu WJ, Homsi J, Davies M, Hwu P. Pharmacokinetics and safety of marqibo (vincristine sulfate liposomes injection) in cancer patients with impaired liver function. J Clin Pharmacol 51(8):1205-12, 8/2011. e-Pub 10/2010. PMID: 20978276.
20. Patel PM, Suciu S, Mortier L, Kruit WH, Robert C, Schadendorf D, Trefzer U, Punt CJ, Dummer R, Davidson N, Becker J, Conry R, Thompson JA, Hwu WJ, Engelen K, Agarwala SS, Keilholz U, Eggermont AM, Spatz A, EORTC Melanoma Group. Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: Final results of a randomised phase III study (EORTC 18032). Eur J Cancer 47(10):1476-83, 7/2011. e-Pub 5/18/2011. PMID: 21600759.
21. Joseph RW, Peddareddigari VR, Liu P, Miller PW, Overwijk WW, Bekele NB, Ross MI, Lee JE, Gershenwald JE, Lucci A, Prieto VG, McMannis JD, Papadopoulos N, Kim K, Homsi J, Bedikian A, Hwu WJ, Hwu P, Radvanyi LG. Impact of clinical and pathologic features on tumor-infiltrating lymphocyte expansion from surgically excised melanoma metastases for adoptive T-cell therapy. Clin Cancer Res 17(14):4882-91, 7/2011. e-Pub 6/2011. PMCID: PMC3139726.
22. Alvarado GC, Papadopoulos NE, Hwu WJ, Bedikian AY, Homsi J, Myers JN, Bronstein Y, Bassett RL, Hwu P, Kim KB. Pelvic computed tomography scans for surveillance in patients with primary melanoma in the head and neck. Melanoma Res 21(2):127-30, 4/2011. e-Pub 12/2010. PMID: 21169870.
23. Davies MA, Liu P, McIntyre S, Kim KB, Papadopoulos N, Hwu WJ, Hwu P, Bedikian A. Prognostic factors for survival in melanoma patients with brain metastases. Cancer-Am Cancer Soc 117(8):1687-96, 4/2011. e-Pub 10/2010. PMID: 20960525.
24. Patnana M, Bronstein Y, Szklaruk J, Bedi DG, Hwu WJ, Gershenwald JE, Prieto VG, Ng CS. Multimethod imaging, staging, and spectrum of manifestations of metastatic melanoma. Clin Radiol 66(3):224-36, 3/2011. e-Pub 1/9/2011. PMID: 21295201.
25. Daud AI, Xu C, Hwu WJ, Urbas P, Andrews S, Papadopoulos NE, Floren LC, Yver A, Deconti RC, Sondak VK. Pharmacokinetic/pharmacodynamic analysis of adjuvant pegylated interferon alpha-2b in patients with resected high-risk melanoma. Cancer Chemother Pharmacol 67(3):657-66, 3/2011. e-Pub 5/28/2010. PMCID: PMC3043235.
26. Homsi J, Bedikian AY, Papadopoulos NE, Kim KB, Hwu WJ, Mahoney SL, Hwu P. Phase 2 open-label study of weekly docosahexaenoic acid-paclitaxel in patients with metastatic uveal melanoma. Melanoma Res 20(6):507-10, 12/2010.
27. Hwu WJ, Knight R, Patnana M, Bassett Jr R, Papadopoulos N, Kim KB, Hwu P, Bedikian A. Phase I safety of lenalidomide plus dacarbazine in patients with metastatic malignant melanoma previously untreated with systemic chemotherapy. Melanoma Res 20(6):501-6, 12/2010.
28. Bedikian AY, Johnson MM, Warneke CL, Papadopoulos NE, Kim KB, Hwu WJ, McIntyre S, Rohlfs M, Homsi J, Hwu P. Does complete response to systemic therapy in patients with stage IV melanoma translate into long-term survival? Melanoma Res. e-Pub 11/22/2010. PMID: 21102360.
29. Neyns B, Tosoni A, Hwu WJ, Reardon DA. Dose-dense temozolomide regimens: antitumor activity, toxicity, and immunomodulatory effects. Cancer 116(12):2868-77, 6/2010. PMID: 20564393.
30. Bedikian AY, Papadopoulos NE, Kim KB, Hwu WJ, Homsi J, Glass MR, Cain S, Rudewicz PJ, Vernillet L, Hwu P. A phase 1B trial of intravenous INO-1001 plus oral temozolomide in subjects with unresectable stage III or stage IV melanoma. Cancer Invest 27:756-63, 2009. PMID: 19440934.
31. Kim KB, Legha SS, Gonzalez R, Anderson CM, Johnson NN, Liu P, Papadopoulos NE, Eton O, Plager C, Buzaid AC, Prieto VG, Hwu WJ, Frost AM, Alvarado G, Hwu P, Ross MI, Gershenwald JE, Lee JE, Mansfield PF, Benjamin RS, Bedikian AY. A randomized phase III trial of biochemotherapy versus interferon-alpha-2b for adjuvant therapy in patients at high risk for melanoma recurrence. Melanoma Res 19:42-9, 2009. PMID: 19430405.
32. Papadopoulos NE, Bedikian A, Ring S, Kim KB, Hwu WJ, Gerber DL, Homsi J, Hwu P. Phase I/II study of a cisplatin-taxol-dacarbazine regimen in metastatic melanoma. Am J Clin Oncol 32:509-14, 2009. PMID: 19506454.
33. Homsi J, Bedikian AY, Kim KB, Papadopoulos NE, Hwu WJ, Mahoney SL, Hwu P. Phase II open-label study of weekly docosahexaenoic acid-paclitaxel in cutaneous and mucosal metastatic melanoma patients. Melanoma Res 19:238-42, 2009. PMID: 19521262.
34. Raizer JJ, Hwu WJ, Panageas KS, Wilton A, Baldwin DE, Bailey E, von Althann C, Lamb LA, Alvarado G, Bilsky MH, Gutin PH. Brain and leptomeningeal metastases from cutaneous melanoma: survival outcomes based on clinical features. Neuro Oncol 10:199-207, 2008. PMID: 18287337.
35. Kim KB, Hwu WJ, Papadopoulos NE, Bedikian AY, Camacho LH, Ng C, Hernandez IM, Frost AM, Jack MA, Hwu P. Phase I study of the combination of docetaxel, temozolomide and cisplatin in patients with metastatic melanoma. Cancer Chemother Pharmacol 64:161-7, 2008. PMID: 19002462.
36. Bedikian AY, Johnson MM, Warneke CL, Papadopoulos N, Kim K, Hwu WJ, McIntyre S, Hwu P. Prognostic factors that determine the long-term survival of patients with unresectable metastatic melanoma. Cancer Invest 26:624-33, 2008. PMID: 18584354.
37. Bedikian AY, Johnson MM, Warneke CL, McIntyre S, Papadopoulos N, Hwu WJ, Kim K, Hwu P. Systemic therapy for unresectable metastatic melanoma: impact of biochemotherapy on long-term survival. J Immunotoxicol 5:201-7, 2008. PMID: 18569391.
38. Mitchell MS, Abrams J, Thompson JA, Kashani-Sabet M, DeConti RC, Hwu WJ, Atkins MB, Whitman E, Ernstoff MS, Haluska FG, Jackowatz JG, Das Gupta TK, Richards JM, Samlowski WE, Costanzi JJ, Aronson FR, Deisseroth AB, Dudek AZ, Jones VE. Randomized trial of an allogenic melanoma lysate vaccine with low-dose interferon-alpha-2b compared with high-dose interferon-alpha-2b for resected stage III cutaneous melanoma. J Clin Oncol 25:2078-85, 2007. PMID: 17513813.
39. Krown SE, Niedzwiecki D, Hwu WJ, Hodgson L, Houghton AN, Haluska FG; Cancer and Leukemia Group B. Phase II study of temozolomide and thalidomide in patients with metastatic melanoma in the brain: high rate of thromboembolic events (CALGB 500102). Cancer 107:1883-90, 2006. PMID: 16986123.
40. Hwu WJ, Panageas KS, Menell JH, Lamb LA, Aird S, Krown SE, Williams LJ, Chapman PB, Livingston PO, Wolchok JD, Houghton AN. Phase II study of temozolomide plus pegylated interferon-alpha-2b for metastatic melanoma. Cancer 106:2445-51, 2006. PMID: 16639739.
41. Hwu WJ. Temozolomide plus pegylated interferon-alpha-2b in patients with metastatic melanoma. Am J Hematol Oncol 5:680-3, 2006.
42. Yeh JJ, Shia J, Hwu WJ, Busam KJ, Paty PB, Guillem JG, Coit DG, Wong WD, Weiser MR. The role of abdominoperineal resection as surgical therapy for anorectal melanoma. Annals Surg 244:1012-7, 2006. PMID: 17122627.
43. Thompson MA, Warner NB, Hwu WJ. Hypertrophic osteoarthropathy associated with metastatic melanoma. Melanoma Res 15:559-61, 2005. PMID: 16314744.
44. Yeh JJ, Weiser MR, Shia J, Hwu WJ. Response of stage IV anal mucosal melanoma to chemotherapy. Lancet Oncol 6:438-9, 2005. PMID: 15925823.
45. Hwu WJ, Lis E, Menell JH, Panageas KS, Lamb LA, Merrell J, Williams LJ, Krown SE, Chapman PB, Livingston PO, Wolchok JD, Houghton AN. Temozolomide plus thalidomide in patients with brain metastases from melanoma: a phase II study. Cancer 103:2590-7, 2005. PMID: 15861414.
46. Chapman PB, Williams L, Salibi N, Hwu WJ, Krown SE, Livingston PO. A phase II trial comparing five dose levels of BEC2 anti-idiotypic monoclonal antibody vaccine that mimics GD3 ganglioside. Vaccine 22:2904-9, 2004. PMID: N/A.
47. Chapman PB, Wu D, Ragupathi G, Lu S, Williams L, Hwu WJ, Johnson D, Livingston PO. Sequential immunization of melanoma patients with GD3 ganglioside vaccine and anti-idiotypic monoclonal antibody that mimics GD3 ganglioside. Clin Cancer Res 10:4717-23, 2004. PMID: 15269144.
48. Ragupathi G, Livingston PO, Hood C, Gathuru J, Krown SE, Chapman PB, Wolchok JD, Williams LJ, Oldfield RC, Hwu WJ. Consistent antibody response against ganglioside GD2 induced in patients with melanoma by a GD2 lactone-keyhole limpet hemocyanin conjugate vaccine plus immunological adjuvant QS-21. Clin Cancer Res 9:5214-20, 2003. PMID: 14614001.
49. Busam KJ, Sachs DL, Coit DG, Halpern A, Hwu WJ. Eruptive melanotic macules and papules associated with adenocarcinoma. J Cutan Pathol 30:463-9, 2003. PMID: 12859746.
50. Wolchok JD, Williams L, Pinto JT, Fleisher M, Krown SE, Hwu WJ, Livingston PO, Chang C, Chapman PB. Phase I trial of high dose paracetamol and carmustine in patients with metastatic melanoma. Melanoma Res 13:189-96, 2003. PMID: 12690304.
51. Hwu WJ, Krown SE, Menell JH, Panageas KS, Merrell J, Lamb LA, Williams LJ, Quinn CJ, Foster T, Chapman PB, Livingston PO, Wolchok JD, Houghton AN. Phase II study of temozolomide plus thalidomide for the treatment of metastatic melanoma. J Clin Oncol 21:3351-6, 2003. PMID: 12947072.
52. Motzer RJ, Amato R, Todd M, Hwu WJ, Cohen R, Baselga J, Muss H, Cooper M, Yu R, Ginsberg MS, Needle M. Phase II trial of antiepidermal growth factor receptor antibody C225 in patients with advanced renal cell carcinoma. Invest New Drugs 21:99-101, 2003. PMID: 12795534.
53. Lohmann CM, Hwu WJ, Iversen K, Jungbluth AA, Busam KJ. Primary malignant melanoma of the oesophagus: a clinical and pathological study with emphasis on the immunophenotype of the tumours for melanocyte differentiation markers and cancer/testis antigens. Melanoma Res 13:595-601, 2003. PMID: 14646623.
54. Chapman PB, Panageas KS, Williams L, Wolchok JD, Livingston PO, Quinn C, Hwu WJ. Clinical results using biochemotherapy as a standard of care in advanced melanoma. Melanoma Res 12:381-7, 2002. PMID: 12170188.
55. Schaed SG, Klimek VM, Panageas KS, Musselli CM, Butterworth L, Hwu WJ, Livingston PO, Williams L, Lewis JJ, Houghton AN, Chapman PB. T-cell responses against tyrosinase 368-376(370D) peptide in HLA*A0201+ melanoma patients: randomized trial comparing incomplete Freund's adjuvant, granulocyte macrophage colony-stimulating factor, and QS-21 as immunological adjuvants. Clin Cancer Res 8:967-72, 2002. PMID: 12006508.
56. Hwu WJ, Krown SE, Panageas KS, Menell JH, Chapman PB, Livingston PO, Williams LJ, Quinn CJ, Houghton AN. Temozolomide plus thalidomide in patients with advanced melanoma: results of a dose-finding trial. J Clin Oncol 20:2610-5, 2002. PMID: 12039921.
57. Pollak JS, Burdge CM, Rosenblatt M, Houston JP, Hwu WJ, Murren J. Treatment of malignant pleural effusions with tunneled long-term drainage catheters. J Vasc Interv Radiol 12:201-8, 2001. PMID: 11265884.
58. Hwu WJ, Raizer J, Panageas KS, Lis E. Treatment of metastatic melanoma in the brain with temozolomide and thalidomide. Lancet Oncol 2:634-5, 2001. PMID: 11902555.
59. Berwick M, Song Y, Roy P, Mahabir S, Elahi A, Coit D, Lewis J, Halpern A, Myskowski P, Brady M, Hwu WJ, Chapman P, Livingston P, Polsky D. Association of DNA damage/repair deficiency with melanoma. J Investigative Dermatology 114:847, 2000.
60. Poggi SH, Madison JF, Hwu WJ, Bayar S, Salem RR. Colonic melanoma, primary or regressed primary. J Clin Gastroenterol 30:441-4, 2000. PMID: 10875478.
61. Hwu WJ, Salem RR, Pollak J, Rosenblatt M, D'Andrea E, Leffert JJ, Faraone S, Marsh JC, Pizzorno G. A clinical-pharmacological evaluation of percutaneous isolated hepatic infusion of doxorubicin in patients with unresectable liver tumors. Oncol Res 11:529-37, 1999. PMID: 10905565.
62. Poo-Hwu WJ, Ariyan S, Lamb L, Papac R, Zelterman D, Hu GL, Brown J, Fischer D, Bolognia J, Buzaid AC. Follow-up recommendations for patients with American Joint Committee on cancer stages I-II malignant melanoma. Cancer 86:2252-8, 1999.
63. Papac RJ, Poo-Hwu WJ. Renal cell carcinoma: a paradigm for a lanthanic disease. Am J Clin Oncol 22:223-231, 1999.
64. Stephens PL, Ariyan S, Ocampo RV, Poo WJ. The predictive value of lymphoscintigraphy for nodal metastases of cutaneous melanoma. Conn Med 63:387-90, 1999. PMID: 10461406.
65. Ariyan S, Poo WJ. Safety and efficacy of isolated perfusion of extremities for recurrent tumor in elderly patients. Surgery 123:335-43, 1998. PMID: 9526527.
66. Schultz MZ, Buzaid AC, Poo WJ. A phase II study of interferon-alpha 2b with dacarbazine, carmustine, cisplatin and tamoxifen in metastatic melanoma. Melanoma Res 7:147-51, 1997. PMID: 9167181.
67. Poo WJ, Guo X, Haslund B, Mozdziesz DE. Immunomodulation and enhancement of antitumor activity by co-administration of 1,3-bis(2-chloroethyl)-1-nitrosourea and thymidine. Biochem Pharmacol 53:705-13, 1997. PMID: 9113090.
68. Ariyan S, Poo WJ, Bolognia J. Regional isolated perfusion of extremities for melanoma: a 20-year experience with drugs other than L-phenylalanine mustard. Plast Reconstr Surg 99:1023-9, 1997. PMID: 9091898.
69. Sasson HN, Poo WJ, Bakas MH, Ariyan S. Prolonged survival in patients with advanced melanoma treated with neoadjuvant chemotherapy followed by resection. Ann Plast Surg 37:286-92, 1996. PMID: 8883727.
70. Mani S, Todd M, Poo WJ. Recombinant beta-interferon in the treatment of patients with metastatic renal cell carcinoma. Am J Clin Oncol 19:187-9, 1996. PMID: 8610647.
71. Mani S, Poo WJ. Single institution experience with recombinant gamma-interferon in the treatment of patients with metastatic renal cell carcinoma. Am J Clin Oncol 19:149-53, 1996. PMID: 8610639.
72. Buzaid AC, Pizzorno G, Marsh JC, Ravikumar TS, Murren JR, Todd M, Strair RK, Poo WJ, Hait WN. Biochemical modulation of 5-fluorouracil with brequinar: results of a phase I study. Cancer Chemother Pharmacol 36:373-8, 1995. PMID: 7634378.
73. Ariyan S, Poo WJ, Bolognia J, Buzaid A, Ariyan T. Multiple primary melanoma: data and significance. Plast Reconstr Surg 96:1384-9, 1995. PMID: 7480238.
74. Mani S, Todd MB, Katz K, Poo WJ. Prognostic factors for survival in patients with metastatic renal cancer treated with biological response modifiers. J Urol 154:35-40, 1995. PMID: 7539867.
75. Buzaid AC, Sandler AB, Hayden CL, Scinto J, Poo WJ, Clark MB, Hotchkiss S. Correlation between lipid-associated sialic acid and tumor burden in melanoma. Int J Biol Markers 9:247-50, 1994. PMID: 7836804.
76. Buzaid AC, Sandler AB, Hayden CL, Scinto J, Poo WJ, Clark MB, Hotchkiss S. Neuron-specific enolase as a tumor marker in metastatic melanoma. Am J Clin Oncol 17:430-1, 1994. PMID: 8092117.
77. Buzaid AC, Sandler AB, Mani S, Curtis AM, Poo WJ, Bolognia JL, Ariyan S. Role of computed tomography in the staging of primary melanoma. J Clin Oncol 11:638-43, 1993. PMID: 8478659.
78. Poo WJ, Conrad L, Janeway CA, Jr. Receptor-directed focusing of lymphokine release by helper T cells. Nature 332:378-80, 1988. PMID: 2965306.
79. Cesario TC, Slater L, Poo WJ, Spindler B, Walter B, Gorse G, Carandang G. The effect of hydrocortisone on the production of gamma-interferon and other lymphokines by human peripheral blood mononuclear cells. J Interferon Res 6:337-47, 1986. PMID: 3021873.
80. Poo MM, Poo WJ, Lam JW. Lateral electrophoresis and diffusion of Concanavalin A receptors in the membrane of embryonic muscle cell. J Cell Biol 76:483-501, 1978. PMID: 10605452.
81. Poo WJ, Hartshorne DJ. Actin crosslinked with glutaldehyde: evidence to suggest an active role for actin in the regulatory mechanism. Biochem Biophys Res Commun 70:406-12, 1976. PMID: 132931.

Invited Articles

1. Trinh VA, Hwu WJ. Chemoprevention for Brain Metastases. Curr Oncol Rep 14(1):63-9, 2/2012. e-Pub 10/18/2011. PMID: 22006097.
2. Noor R, Trinh VA, Kim KB, Hwu WJ. BRAF-targeted therapy for metastatic melanoma: rationale, clinical activity and safety. Clinical Investigation 1(8):1127-1139, 8/2011.
3. Trinh VA, Patel SP, Hwu WJ. The safety of temozolomide in the treatment of malignancies. Expert Opin Drug Saf 8:493-9, 2009. PMID: 19435405.


1. Hwu, WJ. Targeted Therapy for Metastatic Melanoma: From Bench to Bedside. HemOnc Today 10:5-8, 6/2010.


1. Morris D. Groves, John DeGroot, Ivo Tremont, Arthur Forman, Sanghee Kang, Be-Lian Pei, Julie Walker, Diana Schultz, Ying Yuan, Nandita Guha, Wen-Jen Hwu, Nicholas Papadopoulos, Kevin Camphausen*, WK Alfred Yung. A Pilot Study of Systemically Administered Bevacizumab in Patients with Neoplastic Meningitis (NM): Imaging, clinical, CSF and biomarker outcomes. SNO 16th Annual Scientific Meeting, 2011.
2. Hwu WJ, Akerley WL, Stephenson J, Yu MK, Evans BA, Mather G, Swabb EA, Hamid O. Final Report: Combination of MPC-6827 with temozolomide for the treatment of patients with metastatic melanoma. Proc ASCO 28:618 (#8531), 6/2010.

Book Chapters

1. Patnana M, Geshenwald JE, Hwu WJ, Ng CS. Melanoma. In: Oncologic Imaging: A Multidisciplinary Approach: Expert Consult - Online and Print, 1e, 1. Ed(s) PM Silverman. Saunders: Philadelphia, 633-651, 2012. ISBN: 1437722321.

Grant & Contract Support

Title: A Phase I Study to Evaluate the Safety, Tolerability and Efficacy of MK-8353 (formerly SCH 900353) in Subjects with Advanced Solid Tumors
Funding Source: Merck
Role: Principal Investigator
Duration: 2/12/2013 - 2/11/2016
Title: An Exploratory Study of Biologic Effects of BMS-936558 (Anti-PD-1 Monoclonal Antibody) Treatment in Subjects with Advanced Melanoma (Unresectable or Metastatic)
Funding Source: Bristol-Myers Squibb
Role: Principal Investigator
Duration: 2/4/2013 - 2/3/2016
Title: A Phase I Study to Evaluate the Safety, Tolerability and Pharmacokinetics of MEDI4736 in Subjects with Advanced Solid Tumors
Funding Source: MedImmune
Role: Principal Investigator
Duration: 2/2013 - 2/2016
Title: A Rollover Protocol for Patients Who Received CP-675
Funding Source: MedImmune
Role: Principal Investigator
Duration: 5/2012 - 5/2015
Title: A Phase I Study of Agent MK-3475 in Patients with Carcinomas and Melanoma
Funding Source: Merck & Co.
Role: Principal Investigator
Duration: 1/4/2012 - 1/31/2015
Title: Phase I, Open-label, Multicenter, Dose Escalation, Multidose Study of BMS-936559 (MDX-1105) Administered Every 14 Days in Subjects with Selected Advanced or Recurrent Solid Tumors
Funding Source: Bristol Myers
Role: Principal Investigator
Duration: 9/23/2011 - 9/23/2015
Title: A Phase II Trial of High Dose Interleukin-2 (HDIL-2) with Recombinant MAGE-A3 Protein Combined with Adjuvant System AS15 (rMAGE-A3 + AS 15) in Patients with Unresectable or Metastatic Melanoma
Funding Source: GSK Biologicals
Role: Principal Investigator
Duration: 12/15/2010 - 12/31/2014
Title: Project4, A Phase I Study of PAR-1 Gene Targeting Using Neutral Liposmal Small Interfering RNA Delivery in Refractory Advanced Melanoma. UT MD Anderson Cancer Center SPORE in Melanoma
Funding Source: NIH/NCI
Role: Co-Investigator
Principal Investigator: Elizabeth Grimm
Duration: 2010 - 2015
Title: An Exploratory Study of Adjuvant Therapy of Pegylated Interferon-Alpha-2b Plus Melanoma Peptide Vaccine in Patients with Resected, Intermediate–Thickness, Node-Negative Melanoma
Funding Source: Merck (formerly Schering-Plough)
Role: Principal Investigator
Duration: 6/16/2008 - 6/30/2015
Title: Combination Therapy of Advanced Melanoma with Temozolomide, PEG-IFN-Alpha-2b and Adoptive T-Cell Transfer: A Preclinical Study
Funding Source: Merck (formerly Schering-Plough)
Role: Co-Investigator
Principal Investigator: Willem Overwijk
Duration: 2/27/2008 - 2/28/2013
Title: A Multicenter Treatment Protocol for Compassionate Use of Ipilumab (BMS-734016) Monotherapy in Subjects with Unresectable Stage II or Stage IV Melanoma
Funding Source: Bristol-Myers Squibb
Role: Principal Investigator
Duration: 11/20/2007 - 11/30/2013
Title: Randomized Phase II Neoadjuvant Study of Temozolomide Alone or with Pegylated-Interferon-Alpha-2b in Patients with Local or Regional Metastases of Melanoma
Funding Source: Merck (formerly Schering Plough)
Role: Principal Investigator
Duration: 7/31/2006 - 7/31/2013
Title: MDACC Cancer Center SPORE in Melanoma
Funding Source: NIH/NCI
Role: Co-Investigator
Principal Investigator: Elizabeth Grimm
Duration: 12/1/2001 - 8/31/2015

Last updated: 5/6/2014